Press releases

JSR Corporation, a global leader in advanced materials and biotechnology, has announced significant developments in their operations with the expansion of their biologics manufacturing facility situated in Singapore. This strategic move is projected to substantially enhance the company’s production capacity in response to the growing demand for biologics across the Asia-Pacific region.

The expansion project includes the installation of cutting-edge production technology that will enable the facility to produce a wider range of therapeutic proteins, including monoclonal antibodies and other complex biologics. With an increasing number of biopharma companies looking to outsource their production needs, this expansion positions JSR as a key player in the contract manufacturing landscape.

“Our expanded facility will allow us to accommodate more clients and deliver high-quality biologics with faster turnaround times,” said Shunichi Takahashi, CEO of JSR Corporation. “We recognize the pressing need for reliable and scalable biologic production, particularly in a post-pandemic world where vaccines and therapeutics are vital.”

The project, expected to be completed in early 2026, symbolizes JSR's commitment to innovation in biotechnology and positions Singapore as a critical hub for the production of biologics in the Asian market. Moreover, this expansion is projected to create numerous job opportunities, bolstering the local economy and supporting skilled workforce development in the region.

As part of the expansion, JSR is also investing in training programs to ensure that its workforce is equipped with the latest skills and knowledge in biologics manufacturing technology. This includes partnerships with local universities to enhance educational offerings in biomanufacturing processes and quality control.

In addition to expanding its production capabilities, JSR Corporation is actively pursuing partnerships with several emerging biopharma companies. These collaborations are designed to foster innovation in drug development and enable faster access to lifesaving therapies. The company aims to provide tailored solutions to meet the diverse needs of its clients in the rapidly evolving biopharma landscape.

This announcement comes at a time when the global demand for biologics is expected to rise significantly. The market for biologics, including vaccines and monoclonal antibodies, is projected to reach over USD 500 billion by 2027, driven by advances in scientific research and an increasing prevalence of chronic diseases.

JSR Corporation, already a key player in advanced materials such as photopolymers and specialty chemicals, sees this expansion as an opportunity to align its operations with broader trends in the pharmaceutical industry emphasizing speed, efficiency, and regulatory adherence.

As regulatory frameworks continue to evolve across the Asia-Pacific region, JSR is committed to maintaining the highest standards of compliance and quality assurance. The company’s facility will adhere to stringent regulatory guidelines, ensuring that all products meet international quality standards and are safe for public consumption.

Furthermore, this strategic initiative aligns with Singapore’s vision of becoming a global hub for biopharmaceutical innovation. With favorable government policies and a supportive ecosystem for research and development, Singapore continues to attract investment from leading pharmaceutical companies worldwide.

JSR Corporation’s expansion reinforces its commitment to not only meeting market demands but also contributing to the broader community by providing healthcare solutions that are both innovative and accessible. In this regard, the company is poised to play an instrumental role in shaping the future of biologics manufacturing in Asia.